Coherus Oncology (CHRS) EBIT (2013 - 2026)
Coherus Oncology (CHRS) posted EBIT of -$36.2 million for Q1 2026, up 21.21% sequentially from -$45.9 million in Q4 2025, and up 20.43% YoY from -$30.0 million in Q1 2025.
Coherus Oncology (CHRS) EBIT (2013 - 2026) Analysis & Trends
Coherus Oncology has reported EBIT for 14 years, with the latest figure at -$36.2 million in Q1 2026.
- Quarterly EBIT rose 20.43% year-over-year to -$36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$171.8 million (up 3.07% YoY) and the FY2025 annual result came in at -$181.1 million, up 9.28% from the prior year.
- EBIT advanced to -$36.2 million in Q1 2026 per CHRS's latest filing, from -$45.9 million in the prior quarter.
- Over five years, EBIT peaked at -$32.0 million in Q3 2023 and troughed at -$80.9 million in Q1 2022.
- A 5-year average of -$51.6 million and a median of -$45.5 million in 2025 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT plunged 145.37% in 2022, then surged 60.22% in 2023.
- Over 5 years, EBIT stood at -$51.5 million in 2022, then sank by 33.81% to -$68.9 million in 2023, then soared by 34.14% to -$45.4 million in 2024, then fell by 1.09% to -$45.9 million in 2025, then grew by 21.21% to -$36.2 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$36.2 million, -$45.9 million, and -$44.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | -32.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.33 Mn |
| Mar 31, 2026 | -36.15 Mn |
| Dec 31, 2025 | -45.88 Mn |
| Sep 30, 2025 | -44.33 Mn |
| Jun 30, 2025 | -45.49 Mn |
| Mar 31, 2025 | -45.44 Mn |
| Dec 31, 2024 | -45.38 Mn |
| Sep 30, 2024 | -46.86 Mn |
| Jun 30, 2024 | -39.63 Mn |
| Mar 31, 2024 | -67.79 Mn |
| Dec 31, 2023 | -68.91 Mn |
| Sep 30, 2023 | -32.01 Mn |
| Jun 30, 2023 | -34.54 Mn |
| Mar 31, 2023 | -67.75 Mn |
| Dec 31, 2022 | -51.49 Mn |
| Sep 30, 2022 | -80.45 Mn |
| Jun 30, 2022 | -44.01 Mn |
| Mar 31, 2022 | -80.93 Mn |
| Dec 31, 2021 | -39.55 Mn |
| Sep 30, 2021 | -32.79 Mn |